Cinclus Pharma Holding AB (publ)

OM:CINPHA Stock Report

Market Cap: SEK 535.2m

Cinclus Pharma Holding Valuation

Is CINPHA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CINPHA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate CINPHA's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate CINPHA's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CINPHA?

Key metric: As CINPHA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CINPHA. This is calculated by dividing CINPHA's market cap by their current revenue.
What is CINPHA's PS Ratio?
PS Ratio7.9x
SalesSEK 67.51m
Market CapSEK 535.18m

Price to Sales Ratio vs Peers

How does CINPHA's PS Ratio compare to its peers?

The above table shows the PS ratio for CINPHA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average31.5x
ENZY Enzymatica
11.5xn/aSEK 611.7m
CLBIO Corline Biomedical
43.5x47.31%SEK 463.9m
MOB Moberg Pharma
29.8x63.34%SEK 434.3m
ORX Orexo
41.2x16.80%SEK 733.4m
CINPHA Cinclus Pharma Holding
7.9x5.89%SEK 535.2m

Price-To-Sales vs Peers: CINPHA is good value based on its Price-To-Sales Ratio (7.9x) compared to the peer average (31.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CINPHA's PS Ratio compare vs other companies in the SE Pharmaceuticals Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
SECARE Swedencare
1.5x9.14%US$433.89m
INDEX InDex Pharmaceuticals Holding
2.7xn/aUS$27.34m
IRLAB A IRLAB Therapeutics
1.1x25.67%US$11.03m
PMED PEPTONIC medical
2.3xn/aUS$8.45m
CINPHA 7.9xIndustry Avg. 4.0xNo. of Companies12PS01632486480+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CINPHA is expensive based on its Price-To-Sales Ratio (7.9x) compared to the European Pharmaceuticals industry average (4x).

Price to Sales Ratio vs Fair Ratio

What is CINPHA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CINPHA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.9x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: CINPHA is expensive based on its Price-To-Sales Ratio (7.9x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CINPHA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 11.50
SEK 46.25
+302.17%
35.34%SEK 70.00SEK 25.00n/a4
Jun ’27SEK 12.02
SEK 46.25
+284.78%
35.34%SEK 70.00SEK 25.00n/a4
May ’27SEK 12.36
SEK 46.25
+274.19%
35.34%SEK 70.00SEK 25.00n/a4
Apr ’27SEK 16.64
SEK 48.33
+190.46%
38.09%SEK 70.00SEK 25.00n/a3
Mar ’27SEK 17.44
SEK 48.33
+177.14%
38.09%SEK 70.00SEK 25.00n/a3
Feb ’27SEK 17.32
SEK 60.00
+246.42%
16.67%SEK 70.00SEK 50.00n/a2
Jan ’27SEK 19.26
SEK 60.00
+211.53%
16.67%SEK 70.00SEK 50.00n/a2
Dec ’26SEK 17.06
SEK 55.00
+222.39%
9.09%SEK 60.00SEK 50.00n/a2
Nov ’26SEK 16.40
SEK 55.00
+235.37%
9.09%SEK 60.00SEK 50.00n/a2
Oct ’26SEK 17.64
SEK 61.67
+249.58%
16.66%SEK 75.00SEK 50.00n/a3
Sep ’26SEK 16.08
SEK 61.67
+283.50%
16.66%SEK 75.00SEK 50.00n/a3
Aug ’26SEK 17.18
SEK 61.67
+258.94%
16.66%SEK 75.00SEK 50.00n/a3
Jul ’26SEK 15.72
SEK 61.67
+292.28%
16.66%SEK 75.00SEK 50.00n/a3
Jun ’26SEK 15.12
SEK 61.67
+307.85%
16.66%SEK 75.00SEK 50.00SEK 12.023
May ’26SEK 9.95
SEK 61.67
+519.77%
16.66%SEK 75.00SEK 50.00SEK 12.363
Apr ’26SEK 12.00
SEK 61.67
+413.89%
16.66%SEK 75.00SEK 50.00SEK 16.643
Mar ’26SEK 14.58
SEK 61.67
+322.95%
16.66%SEK 75.00SEK 50.00SEK 17.443
Feb ’26SEK 18.98
SEK 63.67
+235.37%
12.85%SEK 75.00SEK 56.00SEK 17.323
Jan ’26SEK 21.38
SEK 63.67
+197.79%
12.85%SEK 75.00SEK 56.00SEK 19.263
Dec ’25SEK 20.00
SEK 63.67
+218.33%
12.85%SEK 75.00SEK 56.00SEK 17.063
Nov ’25SEK 24.61
SEK 63.67
+158.70%
12.85%SEK 75.00SEK 56.00SEK 16.403
Oct ’25SEK 27.96
SEK 63.67
+127.71%
12.85%SEK 75.00SEK 56.00SEK 17.643
Sep ’25SEK 30.50
SEK 67.50
+121.31%
11.11%SEK 75.00SEK 60.00SEK 16.082
SEK 46.25
Fair Value
75.1% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/21 08:43
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerDNB Carnegie
Fredrik ThorRedeye
Kevin SuleRedeye